The formation of subsequent inter-firm R&D partnerships between large pharmaceutical companies and small, entrepreneurial biotechnology firms – how important is inter-organisational trust? Online publication date: Sun, 12-Oct-2008
by John Hagedoorn, Nadine Roijakkers, Hans Van Kranenburg
International Journal of Technology Management (IJTM), Vol. 44, No. 1/2, 2008
Abstract: This paper analyses the role of inter-organisational trust in pharmaceutical biotechnology, an industry characterised by a strong dual market structure. Our main finding is that repeated ties in pairs of large pharmaceutical companies and small, entrepreneurial biotechnology firms, which indicate inter-organisational trust, have a negative effect on subsequent partnering. An explanation for this result is found in specific conditions for R&D partnering in this high-technology dual market structure. Partnerships between a small number of very large companies and a large group of dependent small companies are not characterised by mutual dependence and inter-organisational trust.
Online publication date: Sun, 12-Oct-2008
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Management (IJTM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email firstname.lastname@example.org